DrugPatentWatch Database Preview
Lupin Ltd Company Profile
What is the competitive landscape for LUPIN LTD, and when can generic versions of LUPIN LTD drugs launch?
LUPIN LTD has one hundred and thirty-nine approved drugs.
There is one US patent protecting LUPIN LTD drugs. There are fifteen tentative approvals on LUPIN LTD drugs.
There are two patent family members on LUPIN LTD drugs in two countries and two hundred and eighty-eight supplementary protection certificates in fifteen countries.
Summary for Lupin Ltd
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 117 |
| Ingredients: | 101 |
| NDAs: | 139 |
| Drug Master File Entries: | 194 |
| Patent Litigation for Lupin Ltd: | See patent lawsuits for Lupin Ltd |
| PTAB Cases with Lupin Ltd as petitioner: | See PTAB cases with Lupin Ltd as petitioner |
Drugs and US Patents for Lupin Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | LOSARTAN POTASSIUM | losartan potassium | TABLET;ORAL | 078232-003 | Oct 6, 2010 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 201524-002 | Feb 27, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | CLOMIPRAMINE HYDROCHLORIDE | clomipramine hydrochloride | CAPSULE;ORAL | 209294-002 | Nov 21, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | NADOLOL | nadolol | TABLET;ORAL | 209309-002 | Oct 5, 2017 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | RIFABUTIN | rifabutin | CAPSULE;ORAL | 090033-001 | Feb 24, 2014 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 078946-002 | Mar 21, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lupin Ltd | CELECOXIB | celecoxib | CAPSULE;ORAL | 202240-004 | Jun 9, 2015 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for LUPIN LTD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Oral Suspension | 500 mg/5 mL | ➤ Subscribe | 2014-07-22 |
International Patents for Lupin Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007119249 | Start Trial |
| Germany | 112007000920 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lupin Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0817637 | C00817637/01 | Switzerland | Start Trial | PRODUCT NAME: ABACAVIR + LAMIVUDIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 56977 31.10.2005 |
| 0454511 | SPC/GB98/037 | United Kingdom | Start Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE) (GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS.; REGISTERED: CH 54 250.02 19970815; UK EU/1/97/046/001 19970827; UK EU/1/97/046/002 19970827; UK EU/1/97/046/003 19970827; UK EU/1/97/046/004 19970827; UK EU/1/97/046/005 19970827; UK EU/1/97/046/006 19970827; UK EU/1/97/046/007 19970827; UK EU/1/97/046/008 19970827; UK EU/1/97/046/009 19970827 |
| 0350733 | 2001C/030 | Belgium | Start Trial | PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 1718641 | 2012/008 | Ireland | Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 0733366 | 98C0030 | Belgium | Start Trial | PRODUCT NAME: KALII LOSARTAN, HYDROCHLOROTHIAZIDUM; NAT. REGISTRATION NO/DATE: 922 IS 174 F 3 19980223; FIRST REGISTRATION: FR 338 520.7 19950215 |
| 1506211 | 42/2014 | Austria | Start Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121 |
| 0240228 | C980022 | Netherlands | Start Trial | PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
